Found: 61
Select item for more details and to access through your institution.
Animal Models of Nonalcoholic Fatty Liver Disease--A Starter's Guide.
- Published in:
- Nutrients, 2017, v. 9, n. 10, p. 1072, doi. 10.3390/nu9101072
- By:
- Publication type:
- Article
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information.
- Published in:
- PLoS ONE, 2024, v. 19, n. 2, p. 1, doi. 10.1371/journal.pone.0299487
- By:
- Publication type:
- Article
Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis.
- Published in:
- International Journal of Molecular Sciences, 2013, v. 14, n. 10, p. 19867, doi. 10.3390/ijms141019867
- By:
- Publication type:
- Article
SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus.
- Published in:
- Obesity (19307381), 2014, v. 22, n. 5, p. 1309, doi. 10.1002/oby.20682
- By:
- Publication type:
- Article
A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease.
- Published in:
- Clinical Epigenetics, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13148-021-01142-1
- By:
- Publication type:
- Article
1836-P: Nonalcoholic Steatohepatitis (NASH) Significantly Contribute to ß-Cell Function Impairment Independently of Glucose Tolerance Status.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1836-P
- By:
- Publication type:
- Article
279-LB: NIS4, a Novel Blood Test, Can Identify "At-Risk" NASH (NAS>4 and Fibrosis>2) in T2D Patients.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-279-LB
- By:
- Publication type:
- Article
278-LB: Type 2 Diabetes (T2D) as a Risk Factor for NASH and Significant Liver Fibrosis (F>2) in an International Cohort of 2,363 Patients with Metabolic Steatosis.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-278-LB
- By:
- Publication type:
- Article
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Clinical significance and impact of gastric non‐Helicobacter pylori Helicobacter species in gastric disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1432, doi. 10.1111/apt.17488
- By:
- Publication type:
- Article
Review article: vascular effects of PPARs in the context of NASH.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 2, p. 209, doi. 10.1111/apt.17046
- By:
- Publication type:
- Article
Accurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 11, p. 1188, doi. 10.1111/apt.15710
- By:
- Publication type:
- Article
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 50, n. 2, p. 193, doi. 10.1111/apt.15316
- By:
- Publication type:
- Article
Liver Fibrosis Evaluation Using Real-time Shear Wave Elastography in Hepatitis C-Monoinfected and Human Immunodeficiency Virus/Hepatitis C-Coinfected Patients.
- Published in:
- Journal of Ultrasound in Medicine, 2016, v. 35, n. 6, p. 1299, doi. 10.7863/ultra.15.08066
- By:
- Publication type:
- Article
Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis.
- Published in:
- Biomedicines, 2020, v. 8, n. 12, p. 546, doi. 10.3390/biomedicines8120546
- By:
- Publication type:
- Article
Challenges to Differentiate Hepatitis C Genotype 1 and 6: Results from A Field-Study in Cambodia.
- Published in:
- Infectious Diseases & Therapy, 2020, v. 9, n. 3, p. 657, doi. 10.1007/s40121-020-00304-7
- By:
- Publication type:
- Article
Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease.
- Published in:
- Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2019.00563
- By:
- Publication type:
- Article
The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity.
- Published in:
- Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2019.00082
- By:
- Publication type:
- Article
Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion.
- Published in:
- Viruses (1999-4915), 2019, v. 11, n. 8, p. 687, doi. 10.3390/v11080687
- By:
- Publication type:
- Article
Beneficial Effects of Anti-Interleukin-6 Antibodies on Impaired Gastrointestinal Motility, Inflammation and Increased Colonic Permeability in a Murine Model of Sepsis Are Most Pronounced When Administered in a Preventive Setup.
- Published in:
- PLoS ONE, 2016, v. 11, n. 4, p. 1, doi. 10.1371/journal.pone.0152914
- By:
- Publication type:
- Article
Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features.
- Published in:
- PLoS ONE, 2015, v. 10, n. 11, p. 1, doi. 10.1371/journal.pone.0143380
- By:
- Publication type:
- Article
Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature.
- Published in:
- Journal of Pediatric Gastroenterology & Nutrition, 2024, v. 78, n. 5, p. 1190, doi. 10.1002/jpn3.12156
- By:
- Publication type:
- Article
The Liver and the Cardiovascular System: Two of a Kind?
- Published in:
- 2021
- By:
- Publication type:
- Editorial
Adoptive Cell Transfer of Regulatory T Cells Exacerbates Hepatic Steatosis in High-Fat High-Fructose Diet-Fed Mice.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. N.PAG, doi. 10.3389/fimmu.2020.01711
- By:
- Publication type:
- Article
Identifying Therapeutic Targets for Sepsis Research: A Characterization Study of the Inflammatory Players in the Cecal Ligation and Puncture Model.
- Published in:
- Mediators of Inflammation, 2018, p. 1, doi. 10.1155/2018/5130463
- By:
- Publication type:
- Article
A cross-sectional analysis of the association between testosterone and biopsy-proven non-alcoholic fatty liver disease in men with obesity.
- Published in:
- Endocrine (1355008X), 2023, v. 80, n. 1, p. 54, doi. 10.1007/s12020-022-03245-y
- By:
- Publication type:
- Article
Zonated quantification of immunohistochemistry in normal and steatotic livers.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2023, v. 482, n. 6, p. 1035, doi. 10.1007/s00428-023-03496-8
- By:
- Publication type:
- Article
Towards precision medicine in non-alcoholic fatty liver disease.
- Published in:
- Reviews in Endocrine & Metabolic Disorders, 2023, v. 24, n. 5, p. 885, doi. 10.1007/s11154-023-09820-6
- By:
- Publication type:
- Article
Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.768576
- By:
- Publication type:
- Article
The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.682065
- By:
- Publication type:
- Article
Metabolic dysfunction‐associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3781, doi. 10.1111/dom.15723
- By:
- Publication type:
- Article
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-47919-9
- By:
- Publication type:
- Article
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Publisher Correction: EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
- Published in:
- Diabetologia, 2024, v. 67, n. 11, p. 2375, doi. 10.1007/s00125-024-06196-3
- By:
- Publication type:
- Article
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids.
- Published in:
- Diabetologia, 2013, v. 56, n. 10, p. 2266, doi. 10.1007/s00125-013-2981-2
- By:
- Publication type:
- Article
Practice Recommendations for the Management of MASLD in Primary Care: Consensus Results.
- Published in:
- Diseases, 2024, v. 12, n. 8, p. 180, doi. 10.3390/diseases12080180
- By:
- Publication type:
- Article
Epidemiology and treatment of autoimmune hepatitis.
- Published in:
- Hepatic Medicine: Evidence & Research, 2012, v. 4, p. 1, doi. 10.2147/HMER.S16321
- By:
- Publication type:
- Article
Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis.
- Published in:
- PLoS Medicine, 2014, v. 11, n. 7, p. 1, doi. 10.1371/journal.pmed.1001680
- By:
- Publication type:
- Article
Sustained off‐treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue–induced HBeAg seroconversion.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 6, p. 766, doi. 10.1111/jvh.13084
- By:
- Publication type:
- Article
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
- Published in:
- Nature Communications, 2014, v. 5, n. 6, p. 4309, doi. 10.1038/ncomms5309
- By:
- Publication type:
- Article
Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2020, v. 105, n. 7, p. 2311, doi. 10.1210/clinem/dgaa175
- By:
- Publication type:
- Article
Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41467-019-09524-z
- By:
- Publication type:
- Article
The New Nomenclature for Fatty Liver Disease.
- Published in:
- Journal of Gastrointestinal & Liver Diseases, 2024, v. 33, n. 2, p. 149, doi. 10.15403/jgld-5518
- By:
- Publication type:
- Article
Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD.
- Published in:
- PLoS ONE, 2016, v. 11, n. 12, p. 1, doi. 10.1371/journal.pone.0166048
- By:
- Publication type:
- Article
Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.
- Published in:
- 2016
- By:
- Publication type:
- Editorial
Prediction of presence of oesophageal varices just by shear-wave elastography of the liver and spleen.
- Published in:
- Liver International, 2017, v. 37, n. 9, p. 1406, doi. 10.1111/liv.13446
- By:
- Publication type:
- Article